# OnCo record aveo (company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/companies/aveo/>
  a schema:Organization ;
  onco:kind "company" ;
  schema:identifier "aveo" ;
  schema:name "AVEO Oncology (LG Chem)"@en ;
  schema:description "AVEO Oncology is a Boston company that developed tivozanib (Fotivda), a VEGF-receptor blocking pill used in relapsed kidney cancer, and was acquired by LG Chem in 2023. Its one marketed product now faces first-line immunotherapy combinations, and the TiNivo-2 rechallenge trial was negative."@en ;
  schema:url <https://onco.cc/companies/aveo/>, <https://www.aveooncology.com> ;
  schema:dateModified "2026-09-07"^^xsd:date ;
  schema:citation <https://www.aveooncology.com> ;
  schema:addressCountry "US" ;
  onco:cancers <https://onco.cc/cancers/rcc/> ;
  onco:sections <https://onco.cc/fronts/targeted-therapy/> ;
  onco:drugs <https://onco.cc/drugs/tivozanib/>, <https://onco.cc/drugs/ficlatuzumab/> .